UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Purinergic Signalling and Neurological Diseases: An Update

Burnstock, G; (2017) Purinergic Signalling and Neurological Diseases: An Update. CNS & Neurological Disorders - Drug Targets , 16 (3) pp. 257-265. 10.2174/1871527315666160922104848. Green open access

[thumbnail of Burnstock MS revised(2).pdf]
Burnstock MS revised(2).pdf
Available under License : See the attached licence file.

Download (286kB) | Preview


Purinergic signalling, i.e. ATP as an extracellular signalling molecule and cotransmitter in both peripheral and central neurons, is involved in the physiology of neurotransmission and neuromodulation. Receptors for purines have been cloned and characterised, including 4 subtypes of the P1(adenosine) receptor family, 7 subtypes of the P2X ion channel nucleotide receptor family and 8 subtypes of the P2Y G protein-coupled nucleotide receptor family. The roles of purinergic signalling in diseases of the central nervous system and the potential use of purinergic compounds for their treatment are attracting increasing attention. In this review, the focus is on the findings reported in recent papers and reviews to update knowledge in this field about the involvement of purinergic signalling in Alzheimer’s, Parkinson’s and Huntington’s diseases, multiple sclerosis, amyotrophic lateral sclerosis, degeneration and regeneration after brain injury, stroke, ischaemia, inflammation, migraine, epilepsy, psychiatric disorders, schizophrenia, bipolar disorder, autism, addiction, sleep disorders and brain tumours. The use in particular of P2X7 receptor antagonists for the treatment of neurodegenerative diseases, cancer, depression, stroke and ischaemia, A2A receptor antagonists for Parkinson’s disease and agonists for brain injury and depression and P2X3 receptor antagonists for migraine and seizures has been recommended. P2Y receptors have also been claimed to be involved in some central nervous disorders.

Type: Article
Title: Purinergic Signalling and Neurological Diseases: An Update
Location: United Arab Emirates
Open access status: An open access version is available from UCL Discovery
DOI: 10.2174/1871527315666160922104848
Publisher version: https://doi.org/10.2174/1871527315666160922104848
Language: English
Additional information: The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=10.2174/1871527315666160922104848
Keywords: Alzheimer’s, Parkinson’s, MS, Neuroprotection, Depression, Schizophrenia, Addiction, Epilepsy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences
URI: https://discovery.ucl.ac.uk/id/eprint/1521762
Downloads since deposit
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item